Press Releases | Gilead - Gilead Sciences
WEBJul 25, 2024 · Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024. January 22, 2024. Gilead Provides Update on Phase 3 EVOKE-01 Study. Read the latest news about Gilead's work in COVID-19, HIV, viral hepatitis, cancer and other areas.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% ... - Gilead Sciences
WEBJun 20, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for …
Newsroom | Gilead - Gilead Sciences
WEBRecent Press Releases. September 10, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies. September 05, 2024. Gilead to Present New Trodelvy® Data at the IASLC …
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBFOSTER CITY, Calif., June 20, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial...
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEB4 days ago · Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
Gilead PrEP lenacapavir succeeds in Phase 3 trial - CNBC
WEBJun 20, 2024 · Key Points. Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the lenacapavir shot contracted HIV. Gilead needs ...
Gilead Sciences Announces Completion of Acquisition of CymaBay
WEBFOSTER CITY, Calif., March 22, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq:...
Gilead and Genesis Therapeutics Announce Strategic …
WEBSep 10, 2024 · Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
Gilead Sciences Inc - The New York Times
WEBNews about Gilead Sciences Inc. Commentary and archival information about Gilead Sciences Inc from The New York Times.
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and …
WEB4 days ago · Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment ...